A pregnant patient needs continued TNF inhibition for severe inflammatory arthritis and wishes to minimise fetal drug exposure. Which agent has the

Question

A pregnant patient needs continued TNF inhibition for severe inflammatory arthritis and wishes to minimise fetal drug exposure. Which agent has the least placental transfer?

Accepted Answer

Certolizumab pegol, whose absent Fc region limits active placental transfer

Answer

Golimumab, whose intact Fc region limits active placental transfer

Answer

Infliximab, whose intact Fc region limits active placental transfer

Answer

Etanercept, whose fusion-protein structure eliminates active placental transfer

Answer

Adalimumab, whose intact Fc region limits active placental transfer

Anti-Ro neonatal lupus risk — SCE Rheumatology MCQ

A pregnant patient needs continued TNF inhibition for severe inflammatory arthritis and wishes to minimise fetal drug exposure. Which agent has the least placental transfer?